Outcomes of children with low-risk ALL receiving MRD-guided deintensified therapy
| ALL trial, participating countries . | Patients, n . | Induction phase . | Reinduction phase . | Dexamethasone cumulative dose, mg/m2 . | Anthracyclines cumulative dose, mg/m2 . | Alkylating agents cumulative dose, mg/m2 . | HDMTX cumulative dose, g/m2 . | Maintenance duration . | 5-y EFS/OS, % . |
|---|---|---|---|---|---|---|---|---|---|
| UKALL 2003; UK & Ireland22 | 260* | 3 drugs | 1 | 1388 | 75 | 1000 | None | 2-3 years | 94.4/97.9 |
| Egypt VLR ALL 2011; Egypt† | 200 | 4 drugs | 1 | 546 | 50 | None | 12.5 | 104 weeks | 89.5/95.5 |
| Ma-Spore 2003, Malaysia & Singapore21 | 172 | 3 drugs | 2 | 700 | 120 | 3000 | 8.0 | 104 weeks | 93.2/95.4 |
| DCOG ALL 10; The Netherlands23 | 194 | 7 drugs | 1 | 150 | 120 | 2000 | 20.0 | 104 weeks | 93.1/99 |
| ALL trial, participating countries . | Patients, n . | Induction phase . | Reinduction phase . | Dexamethasone cumulative dose, mg/m2 . | Anthracyclines cumulative dose, mg/m2 . | Alkylating agents cumulative dose, mg/m2 . | HDMTX cumulative dose, g/m2 . | Maintenance duration . | 5-y EFS/OS, % . |
|---|---|---|---|---|---|---|---|---|---|
| UKALL 2003; UK & Ireland22 | 260* | 3 drugs | 1 | 1388 | 75 | 1000 | None | 2-3 years | 94.4/97.9 |
| Egypt VLR ALL 2011; Egypt† | 200 | 4 drugs | 1 | 546 | 50 | None | 12.5 | 104 weeks | 89.5/95.5 |
| Ma-Spore 2003, Malaysia & Singapore21 | 172 | 3 drugs | 2 | 700 | 120 | 3000 | 8.0 | 104 weeks | 93.2/95.4 |
| DCOG ALL 10; The Netherlands23 | 194 | 7 drugs | 1 | 150 | 120 | 2000 | 20.0 | 104 weeks | 93.1/99 |